Exploring topics from pharmacokinetics and tubulin targets to schedule dependence and clinical toxicity profiles, this timely work compiles-in a single source-current information on taxanes and their superior activity against small-cell and non-small-cell lung cancer that will enable researchers to optimize present and future palliative and curative strategies. Representing international efforts to define the full potential of these chemotherapeutic drugs, Taxanes in Lung Cancer Therapy furnishes results from ongoing studies involving novel mechanisms of action for paclitaxel and docetaxel paclitaxel exposure duration as well as drug combinations and sequences phase II trials with paclitaxel in chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) patients the combination of paclitaxel and other active agents, such as cisplatin and ifosfamide, in previously untreated small-cell lung cancer (SCLC) as well as advanced NSCLC comparisons of survival duration, response rates, and toxicity between taxol and other regimens the activity of docetaxel against platinum-resistant/refractory NSCLC and much more! Written by researchers and clinicians at the forefront of the field, Taxanes in Lung Cancer Therapy is an essential resource for oncologists, pulmonologists, cancer researchers, pharmacologists, research and development personnel in the pharmaceutical industry, and graduate and medical school students in these disciplines.